ANIK
Anika Therapeutics, Inc.
ANIK lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ANIK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Strong |
ANIK's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ANIK PE Valuation
ANIK has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ANIK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
ANIK has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ANIK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | — |
| Q3 2026 | -$0.13 | +$2.15 |
| Q2 2026 | -$0.27 | +$3.88 |
| Q1 2026 | -$0.79 | +$3.09 |
| Q4 2025 | -$0.76 | +$3.09 |
| Q3 2025 | -$2.28 | +$4.36 |
| Q2 2025 | -$4.15 | +$0.91 |
| Q1 2025 | -$3.88 | +$1.36 |
| Q4 2024 | -$3.85 | +$1.79 |
ANIK has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ANIK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.6M | +10% |
| Q2 2026 | $32.6M | +16% |
| Q1 2026 | $29.6M | +13% |
| Q3 2025 | $27.8M | -28% |
| Q2 2025 | $28.2M | -33% |
| Q1 2025 | $26.2M | -35% |
| Q3 2024 | $38.8M | -6.5% |
| Q2 2024 | $41.9M | -5.4% |
ANIK's revenue is recovering but still below its 2023 peak: $31M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | -35 points |
| Q2 2026 | 9.1% | +24 points |
| Q1 2026 | -19% | -2.2 points |
| Q4 2025 | 2.1% | N/A |
| Q3 2025 | 32% | +105 points |
| Q2 2025 | -15% | -15 points |
| Q1 2025 | -16% | -3.9 points |
| Q3 2024 | -72% | -54 points |
ANIK has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ANIK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ANIK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +35% |
| Q2 2026 | -$2.1M | -$477K |
| Q1 2026 | -$6.3M | -$3.3M |
| Q4 2025 | $4M | +1351% |
| Q3 2025 | $5M | +31% |
| Q2 2025 | -$1.7M | +$2.8M |
| Q1 2025 | -$3M | -$1M |
| Q4 2024 | $275K | -85% |
ANIK still generates free cash flow, though less than at its 2019 peak: $2M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ANIK on cash flow, with more consistent year-over-year improvement.
ANIK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -329K shares |
| 1 year | -7.2% | -1M shares |
| 3 years | -8.5% | -1.2M shares |
| 5 years | -8.6% | -1.3M shares |
| Available history | -8.4% | -1.2M shares |
ANIK has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $853,000 |
| Q1 2026 | $8.7M |
| Q4 2025 | $5.5M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $4M |
| Q4 2024 | $5.6M |
ANIK spent $15M buying back its own shares over the past year, up 58% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ANIK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -14.7x | Net Cash |
| Q2 2026 | -3.0x | Net Cash |
| Q1 2026 | -7.6x | Net Cash |
| Q4 2025 | -8.8x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q1 2022 | -36.9x | Net Cash |
| Q4 2021 | -10.4x | Net Cash |
| Q3 2021 | -45.8x | Net Cash |
ANIK has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ANIK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 29.4 | Neutral |
ANIK's weekly RSI is 36 (neutral) and its Stochastic is 29 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ANIK PE vs Healthcare Sector
| Metric | ANIK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANIK has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ANIK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.7 | 26% below |
| 20 week MA | $18.9 | 27% below |
| 50 week MA | $15.2 | 9% below |
| 100 week MA | $13.8 | 0.1% above |
| 200 week MA | $19.0 | 27% below |
ANIK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ANIK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.8 | $43.2 | -18% |
| 2021 | $43.2 | $38.0 | -12% |
| 2022 | $38.0 | $27.9 | -27% |
| 2023 | $27.9 | $22.7 | -19% |
| 2024 | $22.7 | $16.2 | -28% |
| 2025 | $16.2 | $9.55 | -41% |
| 2026 YTD | $9.55 | $13.8 | +45% |
ANIK has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.